Diazepam Rektiole Allgen

Diazepam Rektiole Allgen is a rectal suppository containing the benzodiazepine diazepam. It is supplied in an EU market formulation, prescribed when healthcare professionals determine a need for acute management of seizures and related conditions. The product delivers the active ingredient through the rectal route, providing systemic absorption without oral intake. As a Schedule IV prescription medication, it is intended for short‑term use under medical and careful supervision.

Diazepam Rektiole Allgen rectal suppository is indicated for several acute clinical situations where rapid systemic delivery of a benzodiazepine is required.

- Acute seizure control, including status epilepticus, when intravenous access is unavailable or delayed. - Adjunctive therapy for muscle spasm associated with neurological disorders. - Short‑term relief of severe anxiety when oral administration is not feasible. - Sedation prior to diagnostic or therapeutic procedures. - Management of breakthrough seizures in patients already on chronic oral diazepam therapy.

The pharmacologic profile of diazepam can produce a range of adverse effects, most of which are dose‑dependent and reversible after discontinuation.

Common: - Drowsiness or sedation. - Fatigue and weakness. - Impaired coordination or ataxia. - Cognitive slowing or memory difficulty. - Nausea or mild gastrointestinal upset.

Serious: - Respiratory depression, especially with concurrent depressants. - Severe hypotension or cardiovascular collapse. - Paradoxical reactions such as agitation, aggression, or seizures. - Hepatic enzyme elevation or liver injury. - Dependence, tolerance, and withdrawal symptoms with prolonged use.

Because diazepam affects the central nervous system, clinicians should evaluate patient-specific factors and monitor for safety concerns before and during therapy with the rectal formulation.

- Assess respiratory function in patients with COPD, asthma, or sleep apnea. - Use caution in individuals with a history of substance use disorder or dependence. - Avoid use during the first trimester of pregnancy; it is classified as Category D. - Adjust dose in elderly patients due to increased sensitivity and slower metabolism. - Monitor liver function tests in patients with hepatic impairment. - Counsel patients about the risk of impaired driving or operating machinery. - Discontinue gradually to reduce withdrawal risk after prolonged therapy.

Diazepam is metabolized primarily by hepatic CYP enzymes and can interact with many other medications; understanding these interactions helps prevent adverse outcomes.

Avoid: - Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol) due to additive respiratory depression. - Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce diazepam plasma levels. - Potent CYP3A4 inhibitors like ketoconazole or clarithromycin, which can increase diazepam concentrations and toxicity. - Antifungal agents (e.g., itraconazole) that inhibit metabolism and raise systemic exposure.

Use with caution: - Antidepressants, especially SSRIs or MAO inhibitors, which may enhance sedation. - Antihistamines and antihypertensives that can increase drowsiness. - Other benzodiazepines or sedative hypnotics, requiring dose adjustments. - Herbal supplements such as St. John’s wort that may alter enzyme activity.